Vyome Holdings Inc HIND
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market
-
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
-
Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
Trading Information
- Previous Close Price
- $2.03
- Day Range
- $2.01–2.09
- 52-Week Range
- $1.75–6.56
- Bid/Ask
- $1.75 / $2.28
- Shares Outstanding
- 7.02M
- Market Cap
- $14.67M
- Volume/Avg
- 7,585 / 13,577
Key Statistics
- Price/Earnings (Normalized)
- 1.17
- Price/Sales
- 34.82
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 18
- Website
- https://vyometx.com
Valuation
|
Metric
|
HIND
|
|---|---|
Price/Earnings (Normalized) | 1.17 |
Price/Book Value | 2.43 |
Price/Sales | 34.82 |
Price/Cash Flow | — |
Price/Earnings
HIND
Financial Strength
|
Metric
|
HIND
|
|---|---|
Quick Ratio | 4.31 |
Current Ratio | 4.37 |
Interest Coverage | −283.62 |
Quick Ratio
HIND
Profitability
|
Metric
|
HIND
|
|---|---|
Return on Assets (Normalized) | 33.42% |
Return on Equity (Normalized) | 61.90% |
Return on Invested Capital (Normalized) | 43.16% |
Return on Assets
HIND
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^#d^xZ$ | LOCK|@L!?! | $129B | |||
| Moderna Inc
MRNA
| LOCK|%Z@d!F^ | LOCK|>m | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$#<m$? | LOCK|st??B | $77B | |||
| argenx SE ADR
ARGX
| LOCK|RLlYxP# | LOCK|?Tf | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>?B%>^ | LOCK|m$ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%jS%HV | LOCK|Z^pd^ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|jDqST^nG | LOCK|MW<d | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|Ld%%?! | LOCK|G&B | $24B | |||
| Incyte Corp
INCY
| LOCK|Zf&$$r | LOCK|vB | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|F>Y&<# | LOCK|%B | $14B |
United States